All IndicationsNeurology & CNSPhase 3Phase 3Phase 3Phase 2
🧠
Epilepsy
4
Companies
7
Drug Programs
3
Phase 3
0
Upcoming PDUFAs
Competitors
JAZZ
Jazz Pharmaceuticals plc
GWP42003-P
JAZZ
Jazz Pharmaceuticals plc
GWP42003-P 20 mg/kg/day Dose
PHM.MC
PharmaMar, S.A.
Eslicarbazepine acetate 1600 mg
JAZZ
Jazz Pharmaceuticals plc
GWP42006
BHVN
Biohaven
Opakalim
HLUYY
Lundbeck
bexicaserin
BHVN
Biohaven
opakalim
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals plc | GWP42003-P | Phase 3 | — | — | — |
| JAZZ Jazz Pharmaceuticals plc | GWP42003-P 20 mg/kg/day Dose | Phase 3 | — | — | — |
| PHM.MC PharmaMar, S.A. | Eslicarbazepine acetate 1600 mg | Phase 3 | — | — | — |
| JAZZ Jazz Pharmaceuticals plc | GWP42006 | Phase 2 | — | — | — |
| BHVN Biohaven | Opakalim | — | — | — | — |
| HLUYY Lundbeck | bexicaserin | — | — | — | — |
| BHVN Biohaven | opakalim | — | — | — | — |
Development Stage Distribution
Unknown
3
Phase 3
3
Phase 2
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.